Cenduit to Launch Quantum Interactive Solution at DIA 2017
Research Triangle Park, NC – June 12, 2017 – Celebrating its 10-year anniversary, Cenduit LLC, a joint venture between QuintilesIMS and Thermo Fisher Scientific, is showcasing its solutions and expertise as the largest interactive response technology (IRT) specialist in the world at DIA 2017, June 19-21 in Chicago. Cenduit’s new CEO Sam Osman will be present at the show, where the company will be launching its newest rapid study build software, Quantum Interactive™.
A technology-based innovation unlike any other in the market, Quantum Interactive increases IRT quality by creating a functioning prototype of an initial study build within minutes. The tool provides a user-friendly interface to guide the study building process for faster requirements discovery and is highly configurable, regardless of study design.
“The ability to increase agility and reduce timelines is critical for success in clinical studies,” said Kim Lanza-Russo, director of product management, Cenduit. “Quantum Interactive gives sponsors the ability to bypass delays, such as lengthy requirements periods. With this tool, a fully functioning system can be ready in minutes with a higher quality end result.”
Attendees are invited to stop by Cenduit booth #1520 for a demonstration of Quantum Interactive and learn how the company’s IRT solutions can help sponsors increase efficiencies and quality delivery, saving study teams time and resources.
To schedule an appointment to discuss Quantum Interactive, please contact Greyson Feurer at Largemouth Communications, (910) 622-5222, greyson@largemouthpr.com. For more information about Cenduit, please visit www.cenduit.com.
About Cenduit
Cenduit, a joint venture between QuintilesIMS and Thermo Fisher Scientific, is the largest IRT specialist in the world with the expertise to empower sponsors for success by implementing a completely personalized system that puts them in control of their clinical trials. With the needs of investigator sites and patients top of mind, Cenduit offers clinical supply chain intelligence and clinical operations know-how through its IRT-driven services: patient randomization, patient reminders, drug supply management, and eClinical integration. Cenduit and has offices in the US, UK, Switzerland, India, and Japan, and global clinical trial experience in more than 100 countries, interacting with more than 600,000 patients at more than 32,000 sites. For additional information, visit Cenduit online at www.cenduit.com; on Twitter @CenduitLLC or on LinkedIn at www.LinkedIn.com/Company/Cenduit.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
